Proteros Biostructures Expands Successful Protein Crystallography Collaboration With OSI Pharmaceuticals
News Mar 11, 2008
Proteros biostructures GmbH has announced the expansion of its collaboration with OSI Pharmaceuticals, Inc. in the field of protein crystallography. Following the successful delivery of valuable high resolution protein-ligand-structures on multiple kinase targets under Proteros’ Gallery Structure mode with compounds supplied by OSI, Proteros will now provide also Gene-to-Structure services to OSI.
This Gene-to-Structure agreement marks the fifth project under the master service agreement signed in October 2007. Under it Proteros will utilize its capabilities in construct design, protein expression and purification as well as protein structure determination to deliver a de novo protein structure and several protein-ligand-structures on a challenging kinase target to OSI.
Dr. Torsten Neuefeind, Proteros’ Chief Executive Officer, commented: “The successes so far demonstrate that the combination of Proteros’ industrial approach, unique technologies and expertise can quickly generate valuable structural data to meet the highest quality standards required by OSI. We look forward to continuing to demonstrate the value of this collaboration and contributing to accelerating drug discovery programmes at OSI.”
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Empowering Women in Technology Key to Boosting UK EconomyNews
A new report launched at London Stock Exchange for International Women’s Day, reveals the critical role women play in driving economic growth across the UK, with detailed research on 1,279 women-led companies showing a total contribution of £25.9 billion in revenue to the UK economy.READ MORE
Pain's Origins May Be Significantly Different in Males and FemalesNews
Researchers found that a specific manipulation of receptors in the nervous system for the neurotransmitter dopamine impairs chronic pain in male mice, but has no effect on females.READ MORE
Comments | 0 ADD COMMENT
Highly Potent Active Pharmaceutical Ingredients (HPAPI)
May 21 - May 22, 2018